Responses
Oral Presentations
From classics to new: synthetic DMARDs in RA
LB0003 Tofacitinib with and without methotrexate versus adalimumab with methotrexate for the treatment of rheumatoid arthritis: results from oral strategy, a phase 3b/4 randomised trial
Compose a Response to This Article
Other responses
No responses have been published for this article.